Education
About Us
Working with TipRanks
Follow Us
CSL (AU:CSL)
ASX:CSL
CSL Stock Chart & Stats
AU$177.86
-AU$0.78(-0.27%)
At close: 4:00 PM EST
AU$177.86
-AU$0.78(-0.27%)
Day’s Range― - ―
52-Week RangeAU$176.01 - AU$292.49
Previous CloseN/A
Volume375.76K
Average Volume (3M)1.15M
Market Cap
$86.29B
Enterprise ValueAU$133.92B
Total Cash (Recent Filing)$1.52B
Total Debt (Recent Filing)$11.96B
Price to Earnings (P/E)18.6
Beta0.79
Next Earnings
Feb 10, 2026EPS Estimate
6.63Last Dividend Ex-Date
Sep 09, 2025Dividend Yield2.56%
Share Statistics
EPS (TTM)3.58
Shares Outstanding485,151,400
10 Day Avg. Volume1,069,447
30 Day Avg. Volume1,149,153
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue8.94
Enterprise Value/Gross Profit18.20
Enterprise Value/Ebitda26.90
Forecast
1Y Price Target
$251.06Price Target Upside41.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
CSL News
CSL FAQ
What was CSL’s price range in the past 12 months?
CSL lowest share price was AU$176.01 and its highest was AU$292.49 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is $86.29B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Feb 10, 2026 which is in 103 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 18, 2025. The company reported AU$3.582 earnings per share for the quarter, missing the consensus estimate of AU$3.986 by -AU$0.404.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of AU$2.485 which represents an annual dividend yield of 2.56%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 6.63.
How many shares outstanding does CSL have?
CSL has 485,151,400 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of AU$3.582 in its last earnings report, missing expectations of AU$3.986. Following the earnings report the stock price went down -16.888%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in AU:CSL
CSL Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$251.06 (41.15% Upside)
$251.06 (41.15% Upside)
Blogger Sentiment
Bullish
AU:CSL Sentiment 85%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $509.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.93%
12-Months-Change
Fundamentals
Return on Equity
16.36%
Trailing 12-Months
Asset Growth
3.63%
Trailing 12-Months
Company Description
CSL
CSL Limited is a global biotechnology company based in Australia, focused on the development, manufacture, and distribution of innovative biotherapies and vaccines. The company operates primarily in two segments: CSL Behring, which specializes in treating serious and rare diseases through its portfolio of immunoglobulins, clotting factors, and other therapies derived from human plasma; and CSL Seqirus, which is one of the largest influenza vaccine companies in the world, providing seasonal and pandemic vaccines. CSL is committed to improving the lives of patients with serious medical conditions through its cutting-edge research and development.
CSL Company Deck
CSL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
CSL demonstrated strong financial growth and strategic initiatives, including successful product launches and plans to streamline operations and enhance R&D efficiency. However, challenges remain in the form of U.S. policy impacts, competitive pressures in the iron market, and a soft performance in the Seqirus segment.View all AU:CSL earnings summariesCSL Stock 12 Month Forecast
Average Price Target
AU$251.06
▲(41.15% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Options Prices
Currently, No data available
---